The recent discovery of two p53-related genes, p63 and p73, has revealed an additional level of complexity to the study of p53 function. Both genes encode multiple proteins arising from alternative promoter usage and splicing, with transactivation, DNA-binding, and tetramerization domains. Recent data support a role for p63 in squamous and transitional cell carcinomas, as well as in certain lymphomas and thymomas.
Methods
To characterize the involvement of p63 and p73 in the development of osteosarcoma, we analyzed the expression and mutation of TAp63 and TAp73 in six osteosarcoma cell lines and twelve osteosarcoma specimens.
Results
Semiquantitative DNA/PCR analysis revealed that eight (67%) and six (50%) out of twelve osteosarcoma specimens showed significantly reduced levels of p63 and p73 transcription, respectively. Direct sequencing of the entire coding region detected no mutations in cell lines or osteosarcoma specimens.
Conclusions
Our data suggest that low expression of p63 and p73 is relatively common in osteosarcomas and might contribute to their molecular pathogenesis.
YokoyamaR., Schneider-StockR., RadigK., WexT., RoessnerA.: Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosaromas: MDM2 amplification and p53 mutations found in progressive tumors.Pathol Res Pract,194: 615–621, 1998.
2.
KawaguchiK.I., OdaY., SakamotoA., SaitoT., TamiyaS., IwamotoY., TsuneyoshiM.: Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.Mod Pathol,15: 878–888, 2002.
3.
LonardoF., UedaT., HuvosA.G., HealeyJ., LadanyiM.: p53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate.Cancer,79: 1541–1547, 1997.
4.
ChoiH.R., BatsakisJ.G., ZhanF., SturgisE., LunaM.A., El-NaggarA.K.: Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.Hum Pathol,33: 158–164, 2002.
5.
YangA., McKeonF.: p63 and p73: p53 mimics, menaces, and more.Nat Rev Mol Cell Biol,1: 199–207, 2000.
6.
Di ComoC.J., UristM.J., BabayanI., DrobnjakM., HedvatC.V., Teruya-FeldsteinJ., PoharK., HoosA., Cordon-CardoC.: p63 expression profiles in human normal and tumor tissues.Clin Cancer Res,8: 494–501, 2002.
7.
MillsA.A., ZhengB., WangX.J., VogelH., RoopD.R., BradleyA.: p63 is a p53 homologue required for limb and epidermal morphogenesis.Nature,398: 708–713, 1999.
8.
YangA., SchweitzerR., SunD., KaghadM., WalkerN., BronsonR.T., TabinC., SharpeA., CaputD., CrumC., McKeonF.: p63 is essential for regenerative proliferation in limb, craniofacial, and epithelial development.Nature,298: 714–718, 1999.
9.
YangA., KaghadM., WangY., GillettE., FlemingM.D., DotschV., AndrewsN.C., CaputD., McKeonF.: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.Mol Cell,2: 305–316, 1998.
10.
GaiddonC., LokshinM., AhnJ., ZhangT., PrivesC.: A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.Mol Cell Biol,21: 1874–1887, 2001.
11.
HallP.A., CampbellS.J., O'NeillM., RoystonD.J., NylanderK., CareyF.A., KernohanN.M.: Expression of the p53 homologue p63α and dNp63α in normal and neoplastic cells.Carcinogenesis,21: 153–160, 2000.
12.
ChenX.: The p53 family: same response, different signals?Mol Med Today,5: 387–392, 1999.
NomotoS., HarukiN., KondoM., KonishiH., TakahashiT.: Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers.Cancer Res,58: 1380–1383, 1998.
15.
TakahashiH., IchimiyaS., NimuraY., WatanabeM., FurusatoM., WakuiS., YataniR., AizawaS., NakagawaraA.: Mutation, allelotyping and transcription analyses of the p73 gene in prostatic carcinoma.Cancer Res,58: 2076–2077, 1998.
16.
CornP.G., KuerbitzS.J., van NoeselM.M., EstellerM., CompitelloN., BaylinS.B., HermanJ.G.: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5’ CpG island methylation.Cancer Res,59: 3352–3356, 1999.
17.
MaiM., QianC., YokomizoA., TindallD.J., BostwickD., PolychronakosC., SmithD.L., LiuW.: Loss of imprinting and allele switching of p73 in renal cell carcinoma.Oncogene,17: 1739–1741, 1998.
18.
ChiS.G., de Vere WhiteR.W., MeyersF.J., SidersD., LeeF., GumerlockP.H.: p53 in prostate: frequent expressed transition mutations.J Natl Cancer Inst,86: 926–933, 1994.
19.
StieweT., PutzerB.M.: Role of p73 in malignancy: tumor suppressor or oncogene?Cell Death Diff,9: 237–245, 2002.
20.
BodeyB., GrogerA.M., BodeyB.Jr., SiegelS., KaiserH.E.: Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas.Anticancer Res,17: 493–498, 1997.
21.
RadigK., Schneider-StockR., HaeckelC., NeumannW., RoessnerA.: p53 gene mutation in osteosarcomas of low-grade malignancy.Hum Pathol,29: 1310–1316, 1998.
22.
ParkH.R., ParkY.K.: Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone.J Kor Med Sci,10: 360–367, 1995.
23.
SheikhM.S., FornaceA.J.Jr.: Role of p53 family members in apoptosis.J Cell Physiol,182: 171–181, 2000.
24.
ParkB.J., LeeS.J., KimJ.I., LeeS.U., LeeC.H., ChangS.G., ParkJ.H., ChiS.G.: Frequent alteration of p63 expression in human primary bladder carcinomas.Cancer Res,60: 3370–3374, 2000.
25.
QuadeB.J., YangA., WangY., SunD., ParkJ.J., SheetsE.E., CvikoA., FederschneiderJ.M., PetersR., McKeonF.D., CrumC.P.: Expression of the p53 homologue p63 in early cervical neoplasia.Gynecol Oncol,80: 24–29, 2001.
26.
HagiwaraK., McMenaminM.G., MiuraK., HarrisC.C.: Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.Cancer Res,59: 4165–4169, 1999.
27.
SunaharaM., ShishikuraT., TakahashiM., TodoS., YamamotoN., KimuraH., KatoS., IshiokaC., IkawaY., NakagawaraA.: Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer.Oncogene,18: 3761–3765, 1999.
28.
BjorkqvistA.M., Husgafvel-PursiainenK., AnttilaS., KarjalainenA., TammilehtoL., MattsonK., VainioH., KnuutilaS.: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma.Genes Chromosomes Cancer,22: 79–82, 1998.
29.
BockmuhlU., SchwendelA., DietelM., PetersenI.: Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas.Cancer Res,56: 5325–5329, 1996.
30.
ParsaR., YangA., McKeonF., GreenH.: Association of p63 with proliferative potential in normal and neoplastic human keratinocytes.J Investig Dermatol,113: 1099–1105, 1999.
31.
HibiK., TrinkB., PatturajanM., WestraW.H., CaballeroO.L., HillD.E., RatovitskiE.A., JenJ., SidranskyD.: AIS is an oncogene amplified in squamous cell carcinoma.Proc Natl Acad Sci USA,97: 5462–5467, 2000.
32.
WangT.Y., ChenB.F., YangY.C., ChenH., WangY., CvikoA., QuadeB.J., SunD., YangA., McKeonF.D., CrumC.P.: Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases.Hum Pathol,32: 479–496, 2001.
33.
GlickmanJ.N., YangA., ShahsafaeiA., McKeonF., OdzeR.D.: Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.Hum Pathol,32: 1157–1165, 2001.
34.
KaufmannO., FietzeE., MengsJ., DietelM.: Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol,116: 823–830, 2001.
35.
BarbareschiM., PecciariniL., CangiM.G., MacriE., RizzoA., VialeG., DoglioniC.: p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.Am J Surg Pathol,25: 1054–1060, 2001.
36.
ParsonsJ.K., GageW.R., NelsonW.G., De MarzoA.M.: p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.Urology,58: 619–624, 2001.
37.
TannapfelA., SchmelzerS., BenickeM., KlimpfingerM., KohlhawK., MossnerJ., EngelandK., WittekindC.: Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer.J Pathol,195: 163–170, 2001.
38.
KaghadM., BonnetH., YangA., CreancierL., BiscanJ.C., ValentA., MintyA., ChalonP., LeliasJ.M., DumontX., FerraraP., McKeonF., CaputD.: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.Cell,90: 809–819, 1997.
39.
Martinez-DelgadoB., MelendezB., CuadrosM., GarciaM.J., NomdedeuJ., RivasC., Fernandez-PiquerasJ., BenitezJ.: Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas.Int J Cancer,102: 15–19, 2002.
40.
OsadaM., OhbaM., KawaharaC., IshiokaC., KanamaruR., KatohI., IkawaY., NimuraY., NakagawaraA., ObinataM., IkawaS.: Cloning and functional analysis of human p51, which structurally and functionally resembles p53.Nat Med,4: 839–843, 1998.
41.
IkawaS., NakagawaraA., IkawaY.: p53 family genes: structural comparison, expression, and mutation.Cell Death Differ,6: 1154–1161, 1999.
42.
RothJ., DobbelsteinM.: Failure of viral oncoproteins to target the p53-homologue p51A.J Gen Virol,80: 3251–3255, 1999.
